Pulmonary Drugs Market by Drug Class, Indication, Drug Type, Distribution Channel, End-User

List of Tables

[198 Pages Report] The Pulmonary Drugs Market size was estimated at USD 79.35 billion in 2023 and expected to reach USD 86.14 billion in 2024, at a CAGR 8.03% to reach USD 136.27 billion by 2030.

The pulmonary drugs market encompasses a wide range of therapeutic solutions specifically designed for the prevention, diagnosis, and treatment of respiratory diseases. Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 79.35 billion
Estimated Year [2024]	USD 86.14 billion
Forecast Year [2030]	USD 136.27 billion
CAGR (%)	8.03%

Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases

Anticholinergic agents are a class of drugs that block the action of acetylcholine, a neurotransmitter responsible for transmitting impulses in the airways. These medications help reduce bronchoconstriction and airway secretions, making them useful for treating chronic obstructive pulmonary disease (COPD) and asthma. Anti-leukotrienes are medications that combat inflammation in the respiratory system by blocking the effects of leukotrienes, which are chemicals involved in immune responses leading to airway constriction and mucus production. They are used primarily to treat asthma, especially in patients who do not respond well to traditional treatments such as inhaled corticosteroids or beta-2 agonists. Antihistamines work by inhibiting histamine, a chemical mediator released during allergic reactions, thereby reducing allergy symptoms such as sneezing, itching, and nasal congestion. Antihistamines can be beneficial in treating asthma and chronic rhinitis associated with allergies; however, it is primarily intended for pulmonary conditions. Beta-2 agonists are pulmonary drugs that stimulate beta-2 adrenergic receptors on bronchial smooth muscle cells, causing relaxation and bronchodilation, which is essential for managing asthma and COPD symptoms. Combination drugs contain two or more different classes of medications to enhance efficacy while minimizing side effects. They are often prescribed when single-agent therapies do not provide adequate symptom control. Monoclonal antibodies are biological drugs engineered to target specific cellular pathways involved in inflammatory and immune-mediated airway diseases, such as severe asthma. Corticosteroids, both oral and inhaled, are potent anti-inflammatory agents used to treat various pulmonary disorders such as asthma and COPD.

Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis

Allergic rhinitis is an inflammatory condition that impacts the nasal passages due to exposure to allergens, including pollen, dust mites, or animal dander. The most commonly used medications for managing this condition include antihistamines, leukotriene receptor antagonists, and intranasal corticosteroids. Asthma is a chronic inflammatory respiratory disease portraying airway obstruction and bronchospasm. Depending on the severity and individual patient needs, asthma management can involve short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or biologics. Chronic obstructive pulmonary disease (COPD) is a lung disease involving chronic bronchitis and emphysema that results in airflow obstruction. Cystic fibrosis, a genetic disorder, causes the accumulation of thick mucus in the lungs, causing chronic infections and respiratory failure. The primary treatment approach involves targeting the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein with modulators and managing symptoms using bronchodilators, antibiotics, and mucolytics. Pulmonary arterial hypertension (PAH) is a rare, severe disorder leading to high blood pressure in the arteries supplying blood to the lungs. The main classes of drugs utilized to treat PAH include endothelin receptor antagonists (ERAs), prostacyclin analogs or agonists, soluble guanylate cyclase stimulators (sGCS), and phosphodiesterase type 5 inhibitors (PDE-5i).

Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management

Prescription drugs are medications that require a prescription from a licensed healthcare professional before they can be dispensed to patients. These medications undergo rigorous testing and regulatory processes to ensure safety and efficacy before being approved by governing agencies such as the Food & Drug Administration (FDA) or the European Medicines Agency (EMA). Prescription pulmonary drugs offer targeted therapies with advanced mechanisms of action designed to address the underlying causes of respiratory diseases. Generic drugs are bioequivalent to branded drugs in dosage form, strength, route of administration, quality, performance characteristics, and intended use. These drugs enter the market after the patent expiration of their branded counterparts and are typically priced lower than the original products. The cost-effectiveness is a primary factor driving the preference for generic drugs among healthcare providers and patients who require long-term treatments or have limited financial resources.

Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers

Hospital pharmacies are an essential distribution channel for pulmonary drugs, primarily due to their strategic location within healthcare facilities. This enables healthcare professionals to have immediate access to life-saving medications for patients with chronic and acute respiratory disorders. Online pharmacies have emerged as a convenient and cost-effective platform for purchasing pulmonary drugs. They offer advantages such as doorstep delivery, privacy, discounts, and ease of access to medications without needing a physical visit to a pharmacy store. Retail pharmacies constitute a significant distribution channel for pulmonary drugs, owing to their widespread presence and ease of access for patients.

End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals

In the homecare segment, patients with chronic respiratory diseases, including asthma, tuberculosis, and chronic obstructive pulmonary disease (COPD) require regular medication and management. Hospitals serve as critical centers for the treatment of acute exacerbations and severe cases of respiratory disorders. Specialty clinics cater to patients with specific respiratory conditions, including cystic fibrosis, interstitial lung diseases, and pulmonary arterial hypertension (PAH).

Regional Insights

The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pulmonary Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pulmonary Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Anti-Cholinergic Agents
- Anti-Leukotrienes
- Antihistamines
- Beta-2 Agonists
- Combination Drugs
- Monoclonal Antibodies
- Oral & Inhaled Corticosteroids

Indication
- Allergic Rhinitis
- Asthma
- Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Pulmonary Arterial Hypertension

Drug Type
- Generic Drugs
- Prescription Drugs

Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

End-User
- Homecare
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pulmonary Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pulmonary Drugs Market?

3. What are the technology trends and regulatory frameworks in the Pulmonary Drugs Market?

4. What is the market share of the leading vendors in the Pulmonary Drugs Market?

5. Which modes and strategic moves are suitable for entering the Pulmonary Drugs Market?

Product Code: MRR-4316E4E893EF

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
  - 5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
- 5.1.2. Restraints
  - 5.1.2.1. Increasing recall of drugs used for pulmonary conditions
- 5.1.3. Opportunities
  - 5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
  - 5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
- 5.1.4. Challenges
  - 5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
5.2. Market Segmentation Analysis
- 5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
- 5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
- 5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
- 5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
- 5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
5.3. Market Trend Analysis
- 5.3.1. Significant growth in the Americas due to rising respiratory disease prevalence and the presence of major market players developing innovative pulmonary drugs for disease management.
- 5.3.2. Well-established space for collaborative production of innovative pulmonary drugs in the Asia-Pacific substantially backed by the government's financial support for drug commercialization
- 5.3.3. Improving healthcare infrastructure and government support emphasize research and development to meet the pulmonary drug requirement in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Pulmonary Drugs Market, by Drug Class

6.1. Introduction
6.2. Anti-Cholinergic Agents
6.3. Anti-Leukotrienes
6.4. Antihistamines
6.5. Beta-2 Agonists
6.6. Combination Drugs
6.7. Monoclonal Antibodies
6.8. Oral & Inhaled Corticosteroids

7. Pulmonary Drugs Market, by Indication

7.1. Introduction
7.2. Allergic Rhinitis
7.3. Asthma
7.4. Chronic Obstructive Pulmonary Disease
7.5. Cystic Fibrosis
7.6. Pulmonary Arterial Hypertension

8. Pulmonary Drugs Market, by Drug Type

8.1. Introduction
8.2. Generic Drugs
8.3. Prescription Drugs

9. Pulmonary Drugs Market, by Distribution Channel

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Pulmonary Drugs Market, by End-User

10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics

11. Americas Pulmonary Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Pulmonary Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Pulmonary Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
- 14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
- 14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
- 14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
- 14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
- 14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
- 14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
- 14.3.8. U.S. FDA Approves ABRYSVO, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
- 14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
- 14.3.10. US FDA Approves GSK's Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
- 14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
- 14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio